Elbrit Life Sciences To Build A Second Manufacturing Facility In Sikkim To Expand Production Capacity

01 July 2019, Elbrit Life Sciences announced a 2 million USD
investment in setting up of its second manufacturing facility in Singtam,
East Sikkim. 

Elbrit Life Sciences currently owns a manufacturing facility in
Pondicherry with a capacity to manufacture 2 million units of solid
dosage formulations per day. The new facility in Sikkim will have a
production capacity of 4 million units per day. The proposed facility will
be UKMHRA and EUGMP complaint. The planned factory will be a state
of the art infrastructure. The plant will majorly focus on manufacturing
finished solid dosage formulations for its domestic business as well as
export business. Elbrit Life Sciences chose Sikkim its destination for its
upcoming facility because of its emergence as a leading hub for
pharmaceutical manufacturing, favourable geographical conditions,
availability of skilled manpower and excellent co-operation from the state

The firm currently manufactures and markets a wide range of branded
formulations across India with a major focus on cardiovascular, anti-
diabetic and neurology range and overseas markets with a major focus
on nutraceuticals. The company exports a wide range of nutraceutical
products to South East Asia, Russia and Latin American countries. As
the company looks to set a strong foothold in the domestic market and in
the international market, the new facility will play a vital part in the
company’s growth story.

The company’s new manufacturing facility in Sikkim will generate direct
employment for at least 250 people. This will be a part of the company’s
commitment to the Make In India initiative by the Honourable Prime
Minister of India Shri Narendra Modi ji.

The company aims the second manufacturing facility to be operational
by mid of 2020 and expects the regulatory approvals to be completed by
2021. The new facility will help the company to expand its global
footprint both in nutraceutical and pharmaceutical segments.

The company spokesperson also intimated that, the Elbrit Life Sciences
is currently manufacturing 65% of its domestic requirement and 80% of
its overseas requirement in its Pondicherry facility. With the addition of
the Sikkim facility, the company will look to manufacture 100% of its
requirement inhouse.

Elbrit Life Sciences is looking to diversify into Oncology, Gynaecology,
Paediatrics and Critical Care Nutraceuticals in the first half of next fiscal.
Speaking of new product launches, Elbrit Life Sciences has already
launched three new products in the year and three more additional
product launches are lined up in the second half of this fiscal. Elbrit Life
Sciences will constantly launch new products to meet the growing needs
of the Indian demographics.

The company spokesperson also added that the Elbrit Life Sciences is
adding more front line medical representatives both in India and in
overseas markets. By end of this financial year, Elbrit Life Sciences
plans to add an additional 500 front line sales executives in
unrepresented geographies domestically. Currently the company
employs more than 500 medical representatives across India and more
than 100 medical representatives in overseas markets. The company
aims to be among the top 100 firms in the domestic market by end of FY

Elbrit Life Sciences to Expand Its Domestic Footprint With a USD 3 Million Investment From Its Parent Firm Capital Investments

Mumbai, Maharashtra, India

Elbrit Life Sciences has proudly announced that it is expanding its footprint in the domestic pharmaceutical industry. The fast-growing domestic pharmaceutical company is presently in advanced talks with its parent investment firm Capital Investments and a Qatar based investment firm to raise 3 million USD. This major investment is aimed at expanding the company’s domestic footprint in branded formulation business. Elbrit Life Sciences started its operations in 2014 and has since witnessed an impressive growth rate of more than 100% per annum.

“We are planning to use the additional funds to expand geographical footprint and to focus on nephrology, urology, gynaecology, and oncology therapy segments,” said the spokesperson of Elbrit Life Sciences, while talking about the expansion plans. He added that the company majorly operates in South India and has sales force strength of 200 frontline sales representatives. It has 45 brands and 150 SKUs. He further added that, “The company is currently not looking at any acquisitions and instead prefers to take the organic route to fuel further growth.”

In addition, Elbrit Life Sciences is aggressively focusing on cardiovascular, diabetes, neurology and nutraceuticals market in the country. Operating in a country with a population exceeding 1.3 billion, Elbrit Life Sciences has a dedicated WHO-GMP manufacturing facility. Moreover, the pharma company is in the process of upgrading its facilities to foray into export markets.

The company is expecting that this deal may close before the 2nd week of October and once the deal is closed, the company expects to pursue growth opportunities. Furthermore, Elbrit Life Sciences also aims to be amongst the Top 150 pharmaceutical companies by the year 2020. According to the company spokesperson, Elbrit Life Sciences plans to go for an IPO somewhere around the year 2022.

Elbrit Life Sciences Dreams Big on Indian Pharmaceutical Business

‘Elbrit Life Sciences’ today announced the commencement of operations. The company is based in Mumbai, India and will be serving patients across South India in the initial phase.

Elbrit Life Sciences’, a new pharmaceutical company based in Mumbai, India, today opened gates for business in India. The company would be serving the South Indian states initially and aims to cover the entire country with time. According to the sources, the company would be targeting cardiac and diabetes product segments in the present year. Elbrit Life Sciences is a part of a global business group based in UK with investments in science, research and education. The group has significantly invested in next generation healthcare such as genetic therapy, molecular biology, DNA mapping and biomarkers. The group also owns world renowned scientific and academic publishing brands.

Speaking on the occasion, Mr. Prakash, the CEO of the company said, “We are extremely excited to announce the launch of Elbrit Life Science. We will be initially venturing into branded generics in diabetic and cardiac segments. In the near future, we will be adding more innovative and super speciality products to our portfolio. Our goal is to expand into other pharmaceutical segments as well and become a leading player in the market in the times to come.” Mr. Prakash, who was present during the occasion is an Indian origin executive based out in the UK.

According to the sources, the parent group based in UK has invested heavily in Elbrit Life Sciences. Details related to the same are expected to be released in the coming weeks.

The sources also said that the company is aggressively planning to pursue the Indian pharmaceutical space. If experts in the field are to be believed, the launch of  Elbrit Life Sciences’ is likely to change the Indian pharmaceutical sector on its head resulting in better quality and healthy competition. With the major Indian pharmaceutical companies facing tough times over quality issues in the US and Europe, healthy competition in the domestic market is an encouraging sign for patients.